Premium
Clinical outcomes of esophageal stents in patients with malignant esophageal obstruction according to palliative additional treatment
Author(s) -
Kim Ji Yeon,
Kim Sang Gyun,
Lim Joo Hyun,
Im Jong Pil,
Kim Joo Sung,
Jung Hyun Chae
Publication year - 2015
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12280
Subject(s) - medicine , stent , dysphagia , perforation , esophageal stent , tracheoesophageal fistula , surgery , gastric outlet obstruction , palliative care , palliative treatment , fistula , adverse effect , esophageal cancer , cancer , materials science , punching , nursing , metallurgy
Objective To evaluate the efficacy and feasibility of esophageal self‐expanding metal stents (SEMS) insertion for malignant esophageal obstruction (MEO) in patients with or without additional palliative treatment. Methods We retrospectively reviewed the medical records of the patients with SEMS for MEO. Baseline characteristics, changes in Mellow–Pinkas dysphagia score, and adverse events were collected and compared according to the presence and absence of additional palliative treatment. Results Altogether 192 patients underwent 236 SEMS insertion procedures. Esophageal, gastric cardiac and lung cancers were seen in 46.4%, 33.3% and 15.1% of the patients, respectively. Their Mellow–Pinkas score significantly decreased within one week and one month after the SEMS insertion (1.66 ± 0.79 and 1.71 ± 0.87 vs 3.09 ± 0.79, respectively, P = 0.000). Complications occurred in 54 (22.9%) of 236 SEMS insertion; there were 28 (11.9%) stent obstruction, 5 (2.1%) perforation (2.1%), 10 (4.2%) stent migration, 5 (2.1%) tracheoesophageal fistula, but no procedure‐related death. Most complications were managed by inserting additional SEMS. The risk of stent obstruction was significantly higher in uncovered stents than in covered SEMS (OR 3.56, 95% CI 1.39–9.12, P = 0.006). Mean duration to the development of complications was 74.8 ± 111.1 days. Overall survival (169.0 ± 127.8 days vs 96.4 ± 90.6 days, P = 0.000) and stent patency (143.3 ± 123.9 days vs 67.6 ± 71.3 days, P = 0.000) were significantly favorable in patients with SEMS and additional palliative treatments compared with those with SEMS alone. Conclusion SEMS insertion is effective and safe for treating MEO, and additional palliative treatment might lengthen stent patency by prolonging the patient's survival.